FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891956384> ?p ?o ?g. }

• W2891956384 endingPage "325" @default.
• W2891956384 startingPage "325" @default.
• W2891956384 abstract "We investigated the antitumor mechanism of Anthopleura anjunae oligopeptide (AAP-H, YVPGP) in prostate cancer DU-145 cells in vitro and in vivo. Results indicated that AAP-H was nontoxic and exhibited antitumor activities. Cell cycle analysis indicated that AAP-H may arrest DU-145 cells in the S phase. The role of the phosphatidylinositol 3-kinase/protein kinase B/mammalian rapamycin target protein (PI3K/AKT/mTOR) signaling pathway in the antitumor mechanism of APP-H was investigated. Results showed that AAP-H treatment led to dose-dependent reduction in the levels of p-AKT (Ser473), p-PI3K (p85), and p-mTOR (Ser2448), whereas t-AKT and t-PI3K levels remained unaltered compared to the untreated DU-145 cells. Inhibition of PI3K/AKT/mTOR signaling pathway in the DU-145 cells by employing inhibitor LY294002 (10 μM) or rapamycin (20 nM) effectively attenuated AAP-H-induced phosphorylation of AKT and mTOR. At the same time, inhibitor addition further elevated AAP-H-induced cleaved-caspase-3 levels. Furthermore, the effect of AAP-H on tumor growth and the role of the PI3K/AKT/mTOR signaling pathway in nude mouse model were also investigated. Immunohistochemical analysis showed that activated AKT, PI3K, and mTOR levels were reduced in DU-145 xenografts. Western blotting showed that AAP-H treatment resulted in dose-dependent reduction in p-AKT (Ser473), p-PI3K (p85), and p-mTOR (Ser2448) levels, whereas t-AKT and t-PI3K levels remained unaltered. Similarly, Bcl-xL levels decreased, whereas that of Bax increased after AAP-H treatment. AAP-H also increased initiator (caspase 8 and 9) and executor caspase (caspase 3 and 7) levels. Therefore, the antitumor mechanism of APP-H on DU-145 cells may involve regulation of the PI3K/AKT/mTOR signaling pathway, which eventually promotes apoptosis via mitochondrial and death receptor pathways. Thus, the hydrophobic oligopeptide (YVPGP) can be developed as an adjuvant for the prevention or treatment of prostate cancer in the future." @default.
• W2891956384 created "2018-09-27" @default.
• W2891956384 creator A5050089664 @default.
• W2891956384 creator A5053586953 @default.
• W2891956384 creator A5057325455 @default.
• W2891956384 creator A5065156994 @default.
• W2891956384 creator A5069703881 @default.
• W2891956384 creator A5084118879 @default.
• W2891956384 creator A5090590010 @default.
• W2891956384 date "2018-09-11" @default.
• W2891956384 modified "2023-10-18" @default.
• W2891956384 title "Inhibition of Prostate Cancer DU-145 Cells Proliferation by Anthopleura anjunae Oligopeptide (YVPGP) via PI3K/AKT/mTOR Signaling Pathway" @default.
• W2891956384 cites W1519000262 @default.
• W2891956384 cites W1878474114 @default.
• W2891956384 cites W1970908053 @default.
• W2891956384 cites W1975608933 @default.
• W2891956384 cites W1977943009 @default.
• W2891956384 cites W1980792888 @default.
• W2891956384 cites W1981711832 @default.
• W2891956384 cites W1983516907 @default.
• W2891956384 cites W1983645982 @default.
• W2891956384 cites W1987642183 @default.
• W2891956384 cites W1992790335 @default.
• W2891956384 cites W1997304206 @default.
• W2891956384 cites W2007824082 @default.
• W2891956384 cites W2012843314 @default.
• W2891956384 cites W2013685285 @default.
• W2891956384 cites W2018532807 @default.
• W2891956384 cites W2034486568 @default.
• W2891956384 cites W2039452519 @default.
• W2891956384 cites W2041811632 @default.
• W2891956384 cites W2048757913 @default.
• W2891956384 cites W2077195956 @default.
• W2891956384 cites W2077223675 @default.
• W2891956384 cites W2079111811 @default.
• W2891956384 cites W2085928412 @default.
• W2891956384 cites W2091269867 @default.
• W2891956384 cites W2094933981 @default.
• W2891956384 cites W2097259163 @default.
• W2891956384 cites W2098176107 @default.
• W2891956384 cites W2105073777 @default.
• W2891956384 cites W2113194416 @default.
• W2891956384 cites W2126569401 @default.
• W2891956384 cites W2136217164 @default.
• W2891956384 cites W2146964357 @default.
• W2891956384 cites W2151782270 @default.
• W2891956384 cites W2153250887 @default.
• W2891956384 cites W2161832345 @default.
• W2891956384 cites W2169637929 @default.
• W2891956384 cites W2170839629 @default.
• W2891956384 cites W2173055827 @default.
• W2891956384 cites W2194902525 @default.
• W2891956384 cites W2195557884 @default.
• W2891956384 cites W2216089853 @default.
• W2891956384 cites W2271273018 @default.
• W2891956384 cites W2288903023 @default.
• W2891956384 cites W2315246627 @default.
• W2891956384 cites W2334017584 @default.
• W2891956384 cites W2388163742 @default.
• W2891956384 cites W2532154357 @default.
• W2891956384 cites W265492837 @default.
• W2891956384 cites W2729223407 @default.
• W2891956384 cites W2755630341 @default.
• W2891956384 cites W2765839132 @default.
• W2891956384 cites W2774946098 @default.
• W2891956384 cites W2777619250 @default.
• W2891956384 cites W2794610215 @default.
• W2891956384 cites W2797597830 @default.
• W2891956384 cites W2811156570 @default.
• W2891956384 cites W4251622665 @default.
• W2891956384 doi "https://doi.org/10.3390/md16090325" @default.
• W2891956384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6165336" @default.
• W2891956384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30208576" @default.
• W2891956384 hasPublicationYear "2018" @default.
• W2891956384 type Work @default.
• W2891956384 sameAs 2891956384 @default.
• W2891956384 citedByCount "30" @default.
• W2891956384 countsByYear W28919563842019 @default.
• W2891956384 countsByYear W28919563842020 @default.
• W2891956384 countsByYear W28919563842021 @default.
• W2891956384 countsByYear W28919563842022 @default.
• W2891956384 countsByYear W28919563842023 @default.
• W2891956384 crossrefType "journal-article" @default.
• W2891956384 hasAuthorship W2891956384A5050089664 @default.
• W2891956384 hasAuthorship W2891956384A5053586953 @default.
• W2891956384 hasAuthorship W2891956384A5057325455 @default.
• W2891956384 hasAuthorship W2891956384A5065156994 @default.
• W2891956384 hasAuthorship W2891956384A5069703881 @default.
• W2891956384 hasAuthorship W2891956384A5084118879 @default.
• W2891956384 hasAuthorship W2891956384A5090590010 @default.
• W2891956384 hasBestOaLocation W28919563841 @default.
• W2891956384 hasConcept C11960822 @default.
• W2891956384 hasConcept C184235292 @default.
• W2891956384 hasConcept C185592680 @default.
• W2891956384 hasConcept C190283241 @default.
• W2891956384 hasConcept C43060935 @default.
• W2891956384 hasConcept C502942594 @default.
• W2891956384 hasConcept C55493867 @default.

• next